
The Bench to Bedside Initiative (BBI) is starting its 12 week seminar series “From Bench to Bedside: Business Fundamentals for Entrepreneurial Scientists”. The program aims to educate scientists from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University about the fundamentals of starting and building a company in the healthcare industry. The end goal is to help these inventors turn their intellectual property into feasible businesses. The program will finish with a Pitch Day event on December 13th in which scientists will pitch their healthcare solutions.
What to Expect:
Please join us for our kickoff seminar on Tuesday, Sept. 13th. We will be featuring keynote speaker from Memorial Sloan Kettering and BBI alumni teams who have successfully formed startups around university inventions. Guest speakers will be:
-Renier Brentjens, MD PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center and Co-founder of Juno Therapeutics
-Frank Borchetta, JD, Co-Founder, Repairogen
-Kate Rochlin, PhD, Chief Scientific Officer, Immunovent
-Kevin O'Rourke, MD, PhD candidate, York Avenue Diagnostics
Professionals of all backgrounds are welcome to attend the weekly seminars and meet our participating physicians and scientists. All attendees are encouraged to network with industry professionals and inventors, discover healthcare solutions they might be interested in working on, and join teams to build businesses around patented technologies approved by the Cornell University, Memorial Sloan Kettering Cancer Center or Rockefeller University licensing offices.
In May, together with Hacking Health NYC and partner healthcare organizations, BBI successfully piloted a "Commercializing Life Science - Business Matchmaking" event to gather a diverse group of people from academic research, technology, healthcare/medicine and the business communities to address innovation in healthcare. All these efforts lead to the formation of successful and diverse teams that can turn healthcare inventions into feasible businesses.
About BBI:
BBI builds teams around patented technologies at Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University. BBI began as a graduate student club in 2010 and has resulted in the creation of several seed-funded life sciences startups. Today BBI unites scientists from these medical universities and professionals in NYC interested in entrepreneurship and/or venture capital in the life sciences. BBI's mission is to provide scientists in the community with the tools needed to translate their ideas into commercial products that will benefit patients.
About Hacking Health:
Hacking Health is a global movement active in 30+ cities in Canada, the United States, South America, Europe and Asia. Hacking Health NYC organizes regular cafés, meetups, clinics, and workshops in partnership with local digital health stakeholders. It aims to transform healthcare by connecting healthcare professionals with designers, developers, innovators and entrepreneurs to build realistic, human-centric solutions to front-line healthcare problems with the belief that diverse minds and perspectives fuel innovation.
About gyro:human
gyro:human is among the first healthcare agencies be born post-ACA implementation. It was conceived specifically to address this evolving landscape. Based on the idea that human relevance should be above all else – we believe it is the critical ingredient in the healthcare marketing space, representing the most fundamental and profound needs there are.
MD PhD, Co-founder of Juno Therapeutics and Director of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center
Dr. Renier Brentjens is a medical oncologist specializing in the treatment of acute and chronic leukemias. Dr. Brentjens is the co-founder of Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer. In its early stages, the company faced lots of challenges to raise capital from investors to develop their product. Today, Juno Therapeutics is a public clinical-stage company that has proven the success of its solution via clinical trials.
Over $1.2 billion is spent on annual allergy testing, but up to 20% of people with allergy symptoms are misdiagnosed. Immunovent createdh e Local Antibody Mucosal Brush Diagnostic (LAMB-Dx) which is a platform technology that allows for accurate detection and diagnosis of diseases, including airborne and food allergies. LAMB-Dx is gentle, rapid and needle-free, making it ideal for the pediatric population.
Kevin is a co-founder of York Avenue Diagnostics. The company aims to commercialize a diagnostic test discovered by Dr. Manikkam Suthanthiran and others at NYP/Weill Cornell Medical Center. The test is a first of its kind diagnostic that can non-invasively detect kidney rejection by monitoring a genetic signature in urine samples from kidney transplant patients.
His team's business plan was awarded first place at the competition, and the team was awarded a $50,000 grand prize from the Big Red Venture Fund and The Cornell Center for Technology Enterprise and Commercialization.
Repairogen is a revolutionary breakthrough in DNA-based skin repair, reducing risk of skin cancer and improving your skin. It employs proprietary DNA-repair technologies to deliver advanced, scientifically-proven skincare and anti-aging cosmetics. In early 2015, the company joined Kevin M. McGovern Family Center for Venture Development to build their solution.